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Abstract
Background: Phosducin-like protein 3 (PhLP3) forms a ternary complex with the ATP-dependent molecular chaperone CCT
and its folding client tubulin. In vitro studies suggest PhLP3 plays an inhibitory role in b-tubulin folding while conversely in
vivo genetic studies suggest PhLP3 is required for the correct folding of b-tubulin. We have a particular interest in the
cytoskeleton, its chaperones and their role in determining cellular phenotypes associated with high level recombinant
protein expression from mammalian cell expression systems.
Methodology/Principal Findings: As studies into PhLP3 function have been largely carried out in non mammalian systems,
we examined the effect of human PhLP3 over-expression and siRNA silencing using a single murine siRNA on both tubulin
and actin systems in mammalian Chinese hamster ovary (CHO) cell lines. We show that over-expression of PhLP3 promotes
an imbalance of a and b tubulin subunits, microtubule disassembly and cell death. In contrast, b-actin levels are not
obviously perturbed. On-the-other-hand, RNA silencing of PhLP3 increases RhoA-dependent actin filament formation and
focal adhesion formation and promotes a dramatic elongated fibroblast-like change in morphology. This was accompanied
by an increase in phosphorylated MAPK which has been associated with promoting focal adhesion assembly and
maturation. Transient overexpression of PhLP3 in knockdown experiments rescues cells from the morphological change
observed during PhLP3 silencing but mitosis is perturbed, probably reflecting a tipping back of the balance of PhLP3 levels
towards the overexpression state.
Conclusions: Our results support the hypothesis that PhLP3 is important for the maintenance of b-tubulin levels in
mammalian cells but also that its modulation can promote actin-based cytoskeletal remodelling by a mechanism linked
with MAPK phosphorylation and RhoA-dependent changes. PhLP3 levels in mammalian cells are thus finely poised and
represents a novel target for engineering industrially relevant cell lines to evolve lines more suited to suspension or
adherent cell growth.
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Introduction
The phosducin-like family of proteins were first identified,
through phosducin itself, as proteins proposed to sequester the b
and c subunit dimer of G protein (Gbc) thereby inhibiting its
interaction with the a subunit (Ga) and regulating signalling
involving trimeric G-protein coupled receptors in multicellular
organisms [1]. More recently it has emerged that the most widely
conserved members of this family in eukaryotes, namely excepting
mammalian retinal phosducin, act as co-chaperones for the
chaperonin containing TCP1 (CCT) [2,3,4]. Blaauw et al. [5]
established three subgroups of phosducin-like proteins on the basis
of sequence similarity present from plants to humans via yeast and
slime moulds; subtype I, including the original phosducin (Pdc)
and its subsequently discovered more generally expressed human
relative phosducin-like protein 1 (PhLP1), subtype II represented
in humans by PhLP2A and PhLP2B [5,6] and subtype III which
includes human PhLP3 [5].The nomenclature used in this report
with regard to the phosducin-like proteins is detailed and clarified
in Table 1. From studies to date it appears that PhLP1-3 may all
be important as co-chaperones during CCT-assisted protein
folding whilst only Pdc and PhLP1 (which have a high affinity
for Gbc) have a role in G protein signalling, phosducin itself being
a relatively recent evolutionary product that has lost interaction
with CCT (for a review of this area see [7]).
A growing body of evidence implicates PhLP3 in the folding
pathway of the cytoskeletal components actin and b-tubulin. For
example, Stirling and co-workers [4] suggested that PhLP3 (also
referred to as APACD or TXNDC9 in mammals, see [4] and
Table 1) may be involved during the early stages of actin and
btubulin folding (independent of the prefoldin complex). These in
vitro studies demonstrated that PhLP3 had a negative effect on
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activity of CCT. The yeast subtype III orthologue, confusingly
termed Plp1, does not stimulate actin binding by CCT whereas
the subtype II orthologue, Plp2, strongly stimulates both binding
and folding of actin by CCT [2]. In embryonic nematode worms
siRNA silencing of PhLP3 produced defects in astral and spindle
pole microtubules and defective cytokinesis [8], mirroring the
effect of RNA silencing of two PhLP3 homologues in plant
Arabidopsis thaliana (PhLP3a and PhLP3b) that resulted in a
disrupted microtubule network and subsequent defective cell We
have a particular interest in both molecular chaperones and
protein folding [9,10,11] and the cytoskeleton [12,13] with respect
to their roles in determining cellular phenotypes associated with
high level expression of recombinant protein by mammalian cell
expression systems e.g. see [14,15,16]. Proteomic analyses have
also demonstrated a correlation of chaperone and cytoskeletal
protein levels with recombinant protein yields in NS0 cells
engineered to express an IgG4 monoclonal antibody [17]. Indeed,
it is becoming increasingly clear that interactions between the
cytoskeleton, the translational machinery, chaperones, protein
folding/degradation, and the secretory machinery are coordinated
[18], all of which are cellular processes underpinning heterologous
protein production during bioprocessing. In this respect there is
also evidence that the cytoskeletal apparatus interacts functionally
with the translational apparatus and that interference of this
interaction leads to a reduction in protein synthesis [19] whilst
modulation of mRNA translation is known to influence recombi-
nant protein synthesis in mammalian cells [20,21,22]. With regard
to CCT, this chaperone has also been linked to translation in
various cellular contexts, including nascent chain folding on the
ribosome [23], ribosome biogenesis [24], antigen processing [25],
and cytoskeletal biogenesis [12,13,26]. CCT also shows interac-
tions with components of the translational machinery including
elongation and initiation factors [27,28].
In the bioprocessing industry, the gold standard mammalian cell
expression system is the Chinese hamster ovary (CHO) cell [29]
which is adapted to grow in suspension growth in large scale
bioreactors where the cells have a very different morphology to
when grown adherently that presumably requires cytoskeleton
remodelling. With our interest in the cytoskeleton and its role in
determining cellular phenotypes associated with high level
recombinant protein expression from mammalian cell expression
systems, and the fact that the majority of studies into PhLP3
function reported to date have been carried out in non-
mammalian systems, we set out to investigate the role of PhLP3
in cytoskeleton remodelling in the industrially relevant CHO cell
line. Specifically, we investigated the influence of manipulating
PhLP3 levels in mammalian cells and show that over-expression of
human PhLP3 in a mammalian system disrupts a- and b-tubulin
localisation whilst there is an approximate 20% decrease in a-
tubulin levels and an approximate 60% increase in b-tubulin level.
By contrast, neither actin levels nor assembly appeared to be
obviously altered upon over-expression of PhLP3, yet siRNA
silencing of PhLP3 promoted the formation of microfilament
remodelling and RhoA/ROCK-dependent stress fiber formation
which was accompanied by an increase in phosphorylated ERK.
Rescue experiments following siRNA prevent the anchorage-
dependent morphological changes observed during siRNA
silencing but probably reflect a milder overexpression phenotype
with inhibited mitosis and promotion of enlarged polyploid nuclei.
These findings support the hypothesis that PhLP3 is important for
maintaining b-tubulin levels in mammalian cells and that
modulation of PhLP3 levels promotes cytoskeletal remodelling in
a MAPK and RhoA-dependent manner.
Results
Authentic human PhLP3 is expressed in the adherent
CHOK1 cell line
It is reported that recombinant human PhLP3 inhibits CCT
mediated folding of actin in a rabbit reticulocyte lysate in vitro
translation system [4,30]. However, to our knowledge there have
been no reports of the effect of PhLP3 manipulation on the actin/
tubulin cytoskeleton in a mammalian cell culture system.
Successful over-expression of PhLP3 constructs in our adherently
grown CHOK1 model system was initially confirmed by western
blotting. Endogenous PhLP3 was detectable at relatively low levels
in untransfected cells (track 3, top panel, Figure 1A) but increased
greatly when recombinant human PhLP3 was transiently ex-
pressed (tracks 1 and 2). Immunofluorescence confirmed this much
higher expression of PhLP3 in transfected CHOK1 adherent cells
compared with untransfected surrounding cells. Similarly high
levels of PhLP3 expression were seen in GFP-positive cells
generated by co-transfection used to monitor plasmid uptake by,
and transfection of, CHOK1 adherent cells (Figure 1C).
To assess the authenticity of the recombinantly expressed PhLP3
protein, its known activity of binding to CCT [4] was monitored.
CHOK1 adherent cells were transfected with a range of DNA
amounts (100 ng, 500 ng, 1 mg, 2 mg) and binding of CCT
determined in immunoprecipitates generated using antibody to
PhLP3. At the lowest level of PhLP3 over-expression (100 ng of
plasmid) no CCT subunits were detected in immunoprecipitates,
whereas CCTa (and CCTb data not shown) binding was apparent
upon transfection with 500 ng or greater amounts of plasmid
(Figure 1B). When higher amounts of plasmid were transfected (1
and 2 mg) there was not an associated increase in PhLP3 over-
expression compared to the 500 ng transfection and the amounts of
CCTa detected in immunoprecipitation experiments were actually
decreased (Figure 1B). A tagged PhLP3 recombinant protein
(PhLP3V5 - with a V5 tag at its C-terminus) did not interact with
CCTa in this assay (data not shown) and was therefore not used in
further work. This finding suggests that modification of the C-
Table 1. The nomenclature used for the Phosducin like proteins (PLPs) discussed in this manuscript.
Gene (Human) Aliases Protein Name Term used in this manuscript
PDC MEKA Phosducin PDC
PDCL PhLP1 Phosducin-like PhLP1
PDCL2 GCPHLP, PhLP2B Phosducin-like 2 PhLP2B
PDCL3 PhLP2A, VIAF Phosducin-like 3 PhLP2A
TXNDC9 PhLP3, APACD Thioredoxin domain containing 9 PhLP3
doi:10.1371/journal.pone.0028271.t001
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subunits, as observed by Stirling and colleagues [4], though C-
terminal myc-tagging does not prevent CCT binding by PhLP1
constructs [31]. Neither actin nor b-tubulin were detected in the
immunoprecipitated complexes (data not shown).
Increasing PhLP3 expression does not appear to perturb
actin levels or organisation in CHOK1 adherent cells but
results in tubulin re-distribution
Transfection of PhLP3 into CHOK1 cells (or the suspension
CHOcell line LB01,data notshown)didnotaltertheamountsofb-
actin detected by immunoblot (Figure 1A, second panel) or in any
obvious way the intracellular distribution of actin (not shown). In
contrast, over-expression of PhLP3 resulted in a change to the levels
of, and ratio of, a-a n db-tubulin subunits. There was an
approximate 20%decrease ina-tubulin afterPhLP3 overexpression
mirrored by an approximate 60% increase in b-tubulin subunits
(Figure 1A, third and fourth panels), as determined by densitometry
analysis of the immunoblots. This change in the ratio of the a-a n d
b-tubulin subunits was associated with a reorganisation of the
microtubules (Figure 1D). a-tubulin in particular appeared to be
partially redistributed to the nucleoplasm (but not to the nucleolus)
(Figure 1D), a most unusual interphase location for tubulin in
normal cells. Analysis of the supernatant of adherent CHOK1 cells
48 h post-PhLP3 transfection revealed that there was a 2.5-fold
increase in the number of detached cells free in the supernatant (i.e.
not adherent) compared to the controls. Moreover, the viability of
these cells was just 30% (PhLP3 transfected) compared to 80% in
controls (Figure 1E). After 72 h of transfection with 2 mg of plasmid
encoding PhLP3 extensive cell death was evident, suggesting
toxicity of substantial PhLP3 overexpression levels.
Figure 1. Transient expression of PhLP3 in CHOK1 adherent cells promotes tubulin redistribution, an imbalance of a and b-tubulin
subunits and cell death. (A)Anti-PhLP3antibodydetectsfulllengthPhLP3(24 kDa)inCHOK1adherentcellstransientlytransfectedwithhumanPhLP3
(duplicates lane 1 and 2). Endogenous PhLP3 was detected in the plasmid only control (lane 3). b-actin levels are not altered upon PhLP3 overexpression
but this promotes an increase of b-tubulin subunits relative to the control and a decrease in a-tubulin subunits (compare lanes 1 and 2 with lane 3). (B)
Immunoprecipitationof CCTa in CHOK1 cells transiently transfected with PhLP3. CCTa (top panel) and PhLP3 (bottom panel) were detected in cell lysates
transiently transfected with 500 ng–2 mg PhLP3 plasmid and immunoprecipitated with an anti-PhLP3 antibody, but not in plasmid only, untransfected
and antibody only controls. (C) Immunofluorescent detection of PhLP3 in CHOK1 cells transfected with PhLP3. An anti-PhLP3 antibody was used to
identify cells overexpressing PhLP3 (green) and DAPI (blue). (D). PhLP3 overexpression alters tubulin distribution. Immunofluorescent staining of PhLP3
transfected CHOK1 cells with either anti-a tubulin(red) or anti-btubulin(green) specific antibodies detects redistribution of both tubulin subunits
compared to untransfected controls. (E) PhLP3 overexpression in adherent CHOK1 cells promotes the release of cells into the supernatant and decreases
cell viability compared to mock transfected and untransfected controls. Data calculated as mean +/2 SEM of n=2.
doi:10.1371/journal.pone.0028271.g001
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promotes an elongated morphology, anchorage-
dependent growth and an altered actin cytoskeleton
Previous studies demonstrated that PhLP3 is not essential in
Dictyostelium [5] and yeast Plp1 (a type III PLP) is not essential,
but in C.elegans siRNA silencing of PhLP3 resulted in microtubule
defects preventing proper cytokinesis in the embryo [8]. To assess
the effect of PhLP3 silencing in a cultured mammalian cell
system, PhLP3-directed knockdown was conducted using two
CHO cell lines, the CHOK1 (adherent) and LB01 (suspension)
cell lines. Two siRNAs, one derived from human PhLP3 the
other based on mouse PhLP3, were used because they were
commercially available and because the annotated CHO genome
sequence is not in the public domain. PhLP3 silencing, by the
mouse siRNA but not the human siRNA, in CHO LB01 cells was
confirmed by qRT-PCR at the mRNA level (Figure S1) and by
immunoblotting (Figure 2A) which showed an approximate 65%
decrease in endogenous PhLP3 levels consistent with the mRNA
data. Together these data, consisting of the qRT-PCR data
showing a knockdown of PhPL3 at the mRNA level and the
western data showing a knockdown at the protein level, confirm
that the murine siRNA does indeed result in knockdown of the
CHO PhPL3 mRNA. After 72 hours of siRNA silencing
treatment a dramatic change in cell phenotype was observed
with elongation of both cells and nuclei, the latter being also
increased in size (Figure 2, and Figure 3 second panel). This
characteristic morphological change compared with untrans-
fected cells was observed only with the mouse siRNA, not with
the human siRNA, nor with a scrambled sequence (negative
control) siRNA.
The elongated morphology of the cells upon knockdown suggested
cytoskeletal changes, most likely in actin assembly as stress fibres. The
presence of extensive stress fiber formation was indeed confirmed
using phalloidin (Figure 2B). There were no obvious increases in
lamellipodia or membrane ruffles. There was an accompanying
reorganisation of the microtubule network, from a radiating pattern
emanating from a distinct microtubule organising centre (MTOC) to
more extensive elongated parallel microtubule arrays (Figure 2C)
characteristically observed in flat, adherent fibroblast cells with well-
developed stress fibres such as NIH 3T3 cells (Figure 2D). The actin
binding protein vinculin is involved in linking the actin cytoskeleton
with the extracellular matrix (ECM) and immunofluorescence staining
of PhLP3 CHO LB01 knockdown cells for this protein revealed
prominent focal adhesion in the elongated cells that appeared to be
predominately at the cell periphery, in contrast to the staining pattern
in control cells (Figure 2E).
Figure 2. RNAi silencing of PhLP3 in LB01 cells promotes a fibroblast-like morphology and cytoskeletal rearrangement. (A)
Immunoblots using anti-PhLP3 of LB01 cells transfected with mouse siRNA shows a decrease in PhLP3 expression compared to human siRNA and a
scrambled negative control siRNA (top panel). Actin is used as an internal loading control (bottom panel). Note that two PhLP3 products (bands) are
detected in these samples prepared with phosphatase inhibitors while in figure 1A (where they were absent) only one product is detected: PhLP3 is
known to be phosphorylated [45] (see also references in the human PhLP3 Unigene entry UniGene Hs.536122) with the phosphoform displaying
higher apparent molecular weight on SDS gels than the unphosphorylated form. (B) LB01 cells were transfected with mouse PhLP3 siRNA for 72 h
and the cells were fixed and stained for either actin (rhodamine phalloidin) or (C) tubulin (anti-a-tubulin). The microtubule organising center is
indicated by a red arrow. (D) NIH 3T3 mouse fibroblast cells were fixed and stained for F-actin filaments (rhodamine phalloidin, red) and microtubules
(anti-a-tubulin, green). (E) Focal adhesions observed with anti-vinculin in cells transfected with the control plasmid or siRNA silencing plasmid 48 h
and 72 h post transfection.
doi:10.1371/journal.pone.0028271.g002
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morphological changes associated with RNAi mediated
CHO LB01 cell PhLP3 silencing but disrupts mitosis and/
or cytokinesis
To rescue the PhLP3 silenced phenotype, and confirm its cause
as being due to PhLP3 depletion/knockdown, CHO LB01 cells
were co-transfected with mouse PhLP3 siRNA and human PhLP3
cDNA. The basis of this approach is that the murine siRNA used
in this study targets the 39UTR of the mouse mRNA (and the
CHO 39-UTR as shown and described above) at a position where
there is no sequence homology to the human 39-UTR. The
murine siRNA should not therefore knockdown the recombinant
human PhPL3 mRNA upon over-expression of the human cDNA
and thus expression of the recombinant human PhLP3 in the
rescue experiment can be achieved in the presence of the murine
siRNA. To limit the disruption of the microtubule network and
increased cell death evident when cells were transfected with large
amounts (2 mg) of plasmid encoding PhLP3 (Figure 1D and 1E), a
smaller amount (500 ng) of plasmid was used for rescue. Figure 3
shows typical results. While the elongated cell shape was prevented
Figure 3. Rescue of PhLP3 silenced CHO LB01 cells promotes aberrant cell division. LB01 cells were silenced and rescued as described in
the methods section and then fixed and co-stained for PhLP3 (green) and with the nuclear DAPI stain (blue). PhLP3 overexpression in LB01 cells leads
to more ‘rounded’ cells compared to untransfected controls (A v B) whilst siRNA silencing promotes morphological changes including elongated cells
and nuclei and adherent growth (A v C). When LB01 cells were co-transfected with mouse PhLP3 siRNA and human PhLP3 DNA (D and E) the
elongated phenotype observed in the PhLP3 silenced cells was no longer present and thus the cells were considered ‘rescued’. Co-transfected cells
were either in early anaphase (red arrows), late anaphase (green arrow) or exhibited enlarged nuclei (white arrrow).
doi:10.1371/journal.pone.0028271.g003
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top of mouse siRNA, many cells either displayed enlarged nuclei
or showed defects in late stages of mitosis compared to control
transfections suggesting that the microtubule network was
disrupted, if more mildly, as it is just by over-expressing PhLP3.
The only mitotic stage observed in ‘rescued’ cells was either early
or late anaphase which suggests that either progression through
this stage in mitosis was disrupted by suprastoichiometric PhLP3
levels or that cytokinesis was inhibited or delayed, in agreement
with spindle pole defects and aberrant cytokinesis observed during
PhLP3 disruption in C. elegans [8].
The RhoA/ROCK pathway is activated during actin stress
fiber formation in PhLP3 siRNA silenced CHO LB01 cells
The small GTPase Rho A protein (RhoA) has a critical role in
regulating cytoskeletal organisation which includes the formation
of focal adhesions and actin stress fibers in cultured cells [32]. The
rho-dependent serine threonine kinase p160ROCK has been
identified as the major target for Rho [33] and in cultured cells,
the pyrimidine derivative Y-27632 has been shown to specifically
inhibit ROCK-mediated formation of stress fibers [34]. We
evaluated whether this signalling pathway contributed to the
reorganisation of the actin cytoskeleton observed upon PhLP3
silencing. In order to determine this, siRNA mediated knockdown
of PhLP3 in LB01 cells was carried out over a period of 72 h and
cells were collected at 24 h intervals for analysis of activated
RhoA. Activated RhoA (24 kDa) was most strongly detected at
72 hours (Figure 4A), the time point coinciding with the most
dramatic PhLP3 knockdown-dependent changes in cell morphol-
ogy. To investigate RhoA involvement further, PhLP3 silenced
LB01 cells were treated with either 3 mMo r1 0mM of the Rho
inhibitor Y-27632 for 6 h (namely during 72–78 h of silencing).
This did not revert the elongated cell morphology, but did produce
a discernible reorganisation of the actin cytoskeleton characterised
by the substantial loss of the internal stress fibres, a concentration
of actin filaments to the cell periphery and an increased number of
filipodia compared to untreated cells (Figure 4B). These findings
are consistent therefore with the hypothesis that the formation and
stabilisation of the stress fibers observed upon PhLP3 silencing is
RhoA dependent.
Manipulation of PhLP3 levels in CHO LB01 cells is
associated with altered MAPK phosphorylation
The dramatic change in morphology observed upon RNA
silencing of PhLP3 in CHO LB01 cells is associated with the
disassembly and reassembly of focal adhesions (Figure 2E). MAPK
(ERK1/2) has an established role in focal adhesion disassembly
involving calpain-activated cleavage of Rho and cytoskeletal linker
proteins such as talin [35] but more recently MAPK was shown to
also be required for their assembly and maturation [36].
Therefore, the status of MAPK phosphorylation was investigated
during manipulation of PhLP3 levels, by immunoblotting with
parallel examination of actin network organisation (by phalloidin
staining) and, by immunofluorescence, of total MAPK versus
phosphorylated MAPK. Figure 5A shows that there was no
obvious change in the amount or distribution of total MAPK
kinase in PhLP3 silenced cells compared to control cells. However,
the phosphorylated MAPK in control cells was concentrated
around the cell periphery and modestly evident whereas in
silenced cells there was both an increase in amounts of
phosphorylated MAPK and a more uniformly cytoplasmic and
even nuclear distribution. Immunoblotting revealed highest levels
of phosphorylated ERK at 72 h silencing compared to controls
and that this increase was reduced in the presence of the ROCK
inhibitor Y27632 (Fig. 5B). Conversely, during transient over-
expression of PhLP3 there was a decrease in phosphorylated ERK
over 48 h compared to controls (Fig. 5C).
Discussion
We believe the studies here to be the first detailed report of the
effects of manipulating PhLP3 levels on mammalian cells. Our
findings are indicative of effects both on microtubules (principally
manifested when PhLP3 is in excess of its usual amounts) and on
microfilaments (when it is diminished). This is not unexpected,
given that PhLP3 is proposed to modulate the actions of CCT, the
chaperone most implicated in, and required for the folding of,
both tubulin and actin, the required components of microtubules
and microfilaments. Even so, the results obtained do appear to
signify that PhLP3 appears to be important in regulating both of
these cytoskeletal components, not just one or the other to their
mutual exclusion. Indeed, they imply that the balance of PhLP3
levels in mammalian cells is rather crucial for the maintenance of
cell health and the balance of deployment (and functions) of
cytoskeleton subunits in the cytoskeletal network.
PhLP3 interacts with CCT to form a ternary structure with
tubulin and is important in the regulation of b-tubulin folding [4].
Lacefield and Solomon [37] carried out deletion studies in yeast
which showed that while it is non-essential, class III PLP (yeast
Plp1) protects these unicellular organisms from the toxic effects of
excess b-tubulin [38] and they concluded that PhLP3 was involved
in an early step in b-tubulin folding. We show here that in Chinese
hamster ovary cell lines, the overexpression of PhLP3 has dramatic
effects upon microtubule networks, disassembling the interphase
microtubule array, mislocalising b-tubulin to nuclei and upregu-
lating b-tubulin levels while downregulating a-tubulin, an
imbalance likely to influence dimer assembly and certainly one
that is toxic to CHO cells (Figure 1) as observed for such
imbalances in yeast. We note too that human PhLP2A (PDCL3 or
VIAF, see Table 1) is an inhibitor of apoptosis (IAP) interacting
factor that plays a role in caspase activation during apoptosis [39]
demonstrating that at least one of the PLPs plays an active role in
cell death. Interestingly, it has been suggested that in plp1D yeast
cells, aggregation of a-tubulin is a result of the absence of correctly
folded b-tubulin so heterodimers cannot be formed [37].
Determining how this imbalance arises upon PhLP3 over-
expression will be a key factor in determining the role of PhLP3
in tubulin biogenesis.
We present here in Figure 3 findings indicating that knockdown
of PhLP3 (using siRNA derived from mouse sequence) is
permissive of microtubule assembly without obvious defects and
yet it promotes reorganisation of the actin microfilament
cytoskeleton to produce a more elongated anchorage-dependent
phenotype. This contrasts with PhLP3 knockdown studies in C.
elegans and A. thaliana that noted aberrant microtubule architecture
as well as abnormal cytokinesis that could signify affects on actin
too [8,40]. A microtubule-based phenotype did however return
upon partial rescue of CHO PhLP3 knockdown using human
PhLP3 encoding DNA (Figure 3) where defects in mitosis were
indicated by the observation of enlarged multinuclear cells
(polyploidy) or disrupted chromosomal segregation indicative of
delays in early or late anaphase. It is of interest to note that a
temperature-sensitive yeast Plp2 mutant has implicated this
protein in G1/S phase cell cycle progression [41] and it is possible
that PhLP3 too may play a role in regulating chromosome
separation during mitosis in mammalian cells, either directly
through a tubulin folding based mechanism, or as a regulator of
PhLP3 and Cytoskeletal Reorganisation
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CCT might shift the normal balance of its functions for other
clients, including those with known regulatory function in cell
cycle progression, including cdc20, cdh1 and plk1 [42,43] that
between them help to govern the anaphase to metaphase
transition, mitotic exit and entry into S-phase.
Deletion studies in yeast and in vitro suggest that PhLP3 has a
negative effect on actin expression [4] seemingly confirmed here
by the influence of PhLP3 knockdown. Willison and colleagues
have shown that yeast PhLP3 (Plp1) appears to inhibit the binding
of actin to CCT whereas Plp2 (the yeast PhLP2 orthologue)
strongly stimulates CCT-mediated actin folding [2]. If type III
PLPs (human PhLP3 and yeast Plp1) stimulate b-tubulin folding
while type II PLPs (human PhLP2 and yeast Plp2) instead
stimulate actin folding then changing their balance could impact
both tubulin and actin folding in reciprocal manner. Thus, our
findings here in mammalian cells of a ‘fibroblast-like’ anchorage-
dependent morphology induced by siRNA silencing of PhLP3 in
CHO cells could reflect a tipping of this balance, promoting a re-
arrangement of the actin cytoskeleton driving the formation of
RhoA activated actin stress fibers and focal adhesions. The RhoA
effector ROCK, is involved in these cytoskeletal changes since the
selective ROCK inhibitor, Y27632, was observed to disrupts these
actin stress fibers (Figure 4). In addition, these changes in the
cytoskeletal architecture are accompanied by an increase in
phosphorylated MAPK, while over-expression of PhLP3 reduced
MAPK phosphorylation (Figure 5). Recently it was shown that the
MEK-MAPK signalling pathway is required for focal adhesion
Figure 4. RhoA/p160ROCK pathway regulates actin stress fiber formation in PhLP3 siRNA silenced CHO LB01 cells. A commercially
available RhoA-GTP/Rhotekin pull down assay was carried out on siRNA silenced PhLP3 LB01 cells. Samples were collected 24 h, 48 h and 72 h post
transfection and activated RhoA was detected at 72 h post-knockdown with an anti-Rho A antibody but not in plasmid only control cells (A). LB01
cells transfected as in panel A for 72 h were then treated for 24 h with the ROCK inhibitor Y2763 (either 3 mMo r1 0mM), fixed and stained for actin
(rhodamine phalloidin, red). F-actin disassembly was observed at both Y2763 concentrations and the concentration of peripheral actin was observed
with 10 mM Y2763 (B).
doi:10.1371/journal.pone.0028271.g004
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remains to be established whether PhLP3 directly influences the
formation of RhoA activated stress fibers and focal adhesions and
whether phosphorylation of MAPK is a direct or indirect
consequence of PhLP3 siRNA silencing and formation of focal
adhesions, i.e. whether such changes are causal or instead
outcomes and whether they occur by a direct or indirect
mechanism. We note too (as above) that any perturbation of
CCT by manipulating one of its regulators, such as here using
PhLP3, is likely to impact on its many other clients and their
functions that may feedback less directly into cyctoskeletal changes
and could also, or instead, include any function CCT might serve
in the adoption of quarternary, as opposed to tertiary, structure by
its clients including, for example, any role it may play in regulating
in vivo assembly of actin [13]. It is indeed interesting in this context
that knockdown of the CCTe subunit in mammalian cells
destabilises holoCCT assembly, releases CCT subunits to bind
the cytoskeleton as monomers or subassemblies and, especially, is
reported to produce a remarkably similar actin reorganisation-
associated, elongated cell morphology phenotype to that observed
here upon PhLP3 knockdown [44].
In conclusion, we note that activities of PLPs are regulated by
phosphorylation [45], further complicating the analysis of these
important proteins and hence studies focused on expression
levels alone are unlikely to unravel the complete mechanism by
which manipulation of these proteins influences the cytoskeleton.
Despite this, the data presented here collectively shows that
cytoskeleton remodelling and adherent-dependent growth can be
activated in the industrially relevant CHO cell line by
manipulating PhLP3 levels. For the bioprocessing of CHO cell
lines engineered to express recombinant proteins it is necessary
to suspension adapt these cells for growth in largescale
bioreactors. The work we present here suggests that the
reorganisation of the cytoskeleton via the manipulation of
Figure 5. siRNA silencing of PhLP3 promotes MAPK phosphorylation upstream of RhoA activation and PhLP3 overexpression
decreases levels of phosphorylated MAPK in suspension CHO LB01 cells. (A) PhLP3 silenced LB01 cells were fixed and co-stained with either
anti-MAPK (second panel, green) and rhodamine phalloidin (for filamentous actin, red) or anti-phosphorylated MAPK (fourth panel, green) and
rhodamine phalloidin. DAPI was used to detect DNA. Untransfected cells were used as controls (first and third panel). (B) An increase in
phosphorylated MAPK was detected by immunoblotting using an anti-MAPK kinase antibody in cells transfected only with PhLP3 siRNA (lane 2)
compared to cells that had been transfected with PhLP3 siRNA in the presence of the ROCK inhibitor Y2763 (lane 3). Cells treated with either Y2763
only, cells transfected with a ‘scrambled’ negative control siRNA and untransfected cells did not show elevated phosphorylated MAPK levels. (C) CHO
cells were transiently transfected with PhLP3 for either 24 h or 48 h and levels of phosphorylated MAPK were detected by immunoblotting with an
anti-MAPK kinase antibody. Expression levels of phosphorylated MAPK were found to decrease from 24 h to 48 h (compare lanes 1 to 2) and to be
lower than in untransfected cells (lanes 3 and 4).
doi:10.1371/journal.pone.0028271.g005
PhLP3 and Cytoskeletal Reorganisation
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28271PhLP3 levels could therefore be further investigated as a method
by which such cells can be switched between adherent and
suspension culture for bioprocessing.
Materials and Methods
Plasmid Construction
Full length Homo sapiens thioredoxin domain containing 9 mRNA
(Acc no BC005968) was obtained as an IMAGE clone (4073821)
from Geneservice Ltd (U.K.). The full length protein coding
sequence was obtained by PCR using forward primer 59ACG-
TACGGATCCATGGAAGCTGATGCATCTGTT39 and as re-
verse primer either 59GTACGTTCTAGACTAATCATCATCA-
GAGTCTGA39 to obtain an untagged clone or 59GTACGT-
TCTAGACTATCATCATCAGAGTCTGA39 to obtain a clone
witha C-terminal V5tag. PCRproducts weredigested with BamHI
and XbaI and cloned into a modified version of the plasmid vector
pcDNA3.1 V5His-TOPO (Invitrogen) from which the ‘T overhang
cloning site’ was removed by cleavage with BstXI and re-ligation.
GFP plasmid, pEGFP-N1, was obtained from Clontech.
Cell Culture
The CHO derived suspension cell line LB01, engineered to
secrete a recombinant monoclonal antibody [9,10] and the
adherent cell line CHOK1 [46] were kindly provided by Lonza
Biologics plc (UK). LB01 cellsw e r ec u l t u r e di nC DC H O ,a
chemically defined media (Invitrogen, UK) which was supple-
mented with 25 mM methionine sulfoximine (MSX). The cells
were grown in 250 ml shake flasks (Corning Inc, USA) in 5%
CO2 at 37uC, with shaking at 100 rpm and routinely
subcultured every 4 days at 3610
5 cells/ml. CHOK1 adherent
cells were cultured at 5% CO2 and 37uC in Dulbecco’s modified
Eagles medium (DMEM/F-12) (Invitrogen, UK), 10% (v/v)
heat inactivated fetal calf serum (FCS) (Lonza), MEM non
essential amino acids (Invitrogen, UK; 100 mM), L-glutamic
acid and L-asparagine (400 mM), adenosine, cytidine, guanosine
and uridine (20 mM), thymidine (10 mM) and 10 mM L-
glutamine.
RNA Silencing
Double stranded small interfering RNAs (siRNAs) that
corresponded to mouse PhLP3 (Mm_Txndc9_5) and human
PhLP3 (Hs_TXNDC9_3) were obtained from Qiagen, UK. For
immunofluorescence studies, cells were seeded in 24 well plates at
4610
4 cells/well and for immunoblotting in six well plates at
2610
5 cells/well. LB01 On the day of transfection LB01 cells were
plated out in Dulbecco’s modified Eagles medium (DMEM/F-12)
(Gibco UK), 10% (v/v) heat inactivated fetal calf serum (FCS)
(Lonza), MEM non essential amino acids (100 mM), L-glutamic
acid and L-asparagine (400 mM), adenosine, cytidine, guanosine
and uridine (20 mM) and thymidine (10 mM) to allow them to
adhere to the culture dish. CHOK1 adherent cells were cultured
as described above. Cells were transfected with either 150 ng
siRNA (for 24 well plates) or 37.5 ng siRNA (diluted into the
appropriate culture media) and either 12 mlo r3ml of Hiperfect
transfection reagent respectively, according to the manufacturers’
protocol (Qiagen, UK). Cells were then harvested post-siRNA
transfections for analysis at the time points described in the figure
legends. For PhLP3 RNAi rescue experiments, CHOK1 cells were
co-transfected with 37.5 ng siRNA and 500 ng plasmid for
transient over-expression of PhLP3 as described below using
Hiperfect as the transfection reagent as described by the
manufacturer.
Primary Antibodies used for Immunoblotting and
Immunofluorescence
The following antibodies were used and sourced as indicated;
ab56600 (an anti-thioredoxin domain containing 9 (PhLP3))
mouse monoclonal antibody, Abcam, UK; V8012 (anti-V5 clone
V5-10) mouse monoclonal antibody, Sigma UK; AF1230 (anti-
human/rat/mouse ERK2 rabbit polyclonal antibody which also
recognises ERK1, R&D Systems, UK); 4370 (anti-phospho-p44/
42 MAPK (ERK1/2), New England Biolabs, UK); V9131 (anti-
vinculin) mouse monoclonal, Sigma, UK. The CCTa and CCTb
subunit antibodies (rabbit polyclonal) were gifts from Dr M Smith,
University of Kent, UK; AC-15, anti-b-actin mouse monoclonal
antibody (Sigma, UK); TAT (anti-a tubulin mouse monoclonal
antibody) and KMX, anti-b-tubulin mouse monoclonal antibodies
were gifts from Professor K. Gull (University of Oxford, UK). The
anti-GFP mouse monoclonal antibody 3E1 was a gift from
Professor W. Gullick (University of Kent, UK).
Transient DNA Transfections for the Over-Expression of
PhLP3
For over-expression studies, the appropriate amount of
expression vector (500 ng or 1 mg as described in the figure
legend) was transfected into LB01 cells which had been seeded at
1610
6 cells/well in a 24 well plate using Fugene HD (Roche
Diagnostics Ltd, UK) transfection reagent according to the
manufacturer’s instructions. CHOK1 adherent cells were seeded
at either 4610
4 cells/well (for immunofluorescence) or 1610
6
cells/well (for immunoblotting) and transfected using Lipofecta-
mine 2000 (Invitrogen, UK) according to the manufacturer’s
instructions.
Immunoprecipitation
For immunoprecipitation studies, cells were seeded at 3610
5
cells/well in 24 well plates and transfected with either the PhLP3
or PhLP3V5 encoding plasmid constructs as described above.
Twenty four hours post-transfection, the cells were washed 36
with 1 ml of PBS and then lysed in 20 mM HEPES, pH 7.2,
100 mM NaCl, 1% (v/v) Triton X-100, 50 mM sodium fluoride,
1 mM sodium vanadate, 10 mM sodium b-glycerphosphate and
Complete Protease Inhibitor Cocktail (Roche, UK). For immu-
noprecipitation, 2 mg of antibody was added to 200 mg of lysed
protein and incubated for 2 h on ice. 25 ml of Protein A Sepharose
slurry (Sigma, P3391) was then incubated with shaking with the
antibody/lysate solution for 1.5 h at 4uC. The Protein A beads
were then washed 36in PBS and then 20 mlo f2 6Laemmli SDS-
PAGE sample buffer added, the samples boiled for 2 min,
centrifuged in a bench top centrifuge at 13,000 rpm (17900 rcf)
for 1 min and the eluted protein analysed by SDS-PAGE.
SDS-PAGE Sample Preparation
Suspension cells were pelleted for 5 min in a benchtop
microcentrifuge and the supernatant removed. The pelleted cells
were washed twice in cold PBS before ice cold lysis buffer (see
above) was added and the cells left for 5 min on ice to lyse.
Adherent cells were washed twice in ice cold PBS, prior to
addition of lysis buffer and then scraped with a Fisherbrand cell
scraper (Fisher Scientific, UK). The lysate was then centrifuged at
13,000 rpm (17900 rcf) for two minutes and stored at 280uC until
required for SDS-PAGE analysis.
SDS PAGE Electrophoresis and Immunoblotting
SDS-PAGE was used to analyse proteins on 4–20% polyacryl-
amide gels (BioRad Labs Inc, UK). Proteins were semi-dry blotted
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UK). Non-specific binding sites were blocked with 4% Marvel milk
proteins diluted in PBS for 60 min at room temperature.
Immunoblots were incubated with primary antibodies (see below),
which had been diluted in PBS/0.1% Tween 20 at 4uC overnight.
The immunoblots were washed 565 min in PBS/0.1% Tween 20,
probed with either rabbit anti-mouse IgG antibody or goat anti-
rabbit IgG antibody conjugated to HRP (Sigma, UK) for 1 h at
room temperature and washed again. The immunoblots were
visualised on Hyper Film using the commercially available ssECL
detection kit (Amersham Biosciences, UK).
Indirect Immunofluorescence
Cells were seeded onto coverslips at 2610
5 cells/well in a 24
well plate and after the appropriate treatment were washed 26in
PBS, fixed for 10 min with 4% (w/v) paraformaldehyde in PBS,
permeabilised in 0.1% Triton X-100/PBS for 5 min at 4uC,
washed with PBS and non-specific binding sites blocked with 3%
BSA in PBS for 20 min at room temperature. After the addition of
primary antibody (diluted in 3% BSA in PBS) for 1 h at room
temperature, cells were washed with 3% BSA in PBS and either
anti-mouse FITC or anti-mouse TRITC conjugated rabbit IgG
antibody (Sigma, UK) diluted 1:100 or anti-rabbit FITC
conjugated goat IgG antibody diluted 1:64 with 3% BSA in PBS
was added and left for 1 h at room temperature in the dark.
Filamentous actin was detected using Phalloidin Alexa Fluor 546
(Molecular Probes, UK) which was diluted 1:80 and incubated
with the cells for 30 min. GFP (green fluorescence protein) was
detected with 3E1 (an anti-GFP mouse monoclonal antibody). The
cells were then washed and coverslips mounted in Mowiol
containing p-phenyldiamine (1 mg/ml) before being left overnight
at 4uC prior to microscopy using a Leitz DMBR immunofluores-
cence microscope.
Activated RhoA Binding Assay
Activation of RhoA was determined using a commercially
available pull down assay based upon detecting the interaction of
the active GTP-bound RhoA with the Rho-binding domain (RBD)
of Rhotekin (RhoA Activation Assay Kit, STA-403-A, Cell Biolabs
Inc, USA). For this assay, 2610
5 cells were seeded in 6 well plates
and siRNA silencing of PhLP3 was carried out as described above.
Cells were subsequently collected 24, 48 and 72 h post
transfection, lysed in a buffer consisting of 25 mM HEPES,
pH 7.5, 150 mM NaCl, 1% Nonidet-40, 10 mM MgCl2, 1m M
EDTA and 2% glycerol, and stored at 280uC prior to analysis by
immunblot with an anti-RhoA antibody as described in the
manufacturer’s protocol.
Inhibition of ROCK with Y27632
The Rho-kinase (ROCK) specific inhibitor Y27632 (Sigma
Aldrich, UK) was added either at 3 mMo r1 0mM to LB01 cells in
which PhLP3 had been silenced for 72 h (as described above). The
cells were incubated at 37uC for 6 h and then processed for
immunofluorescence whereby actin filaments were detected with
Phalloidin Alexa Fluor 546 (Molecular Probes, UK) as described
above in the immunofluorescence section.
Densitometry
Image J public access software (http://rsbweb.nih.gov/ij/
features.html) (a Java image processing programme) was used for
densitometry measurements of bands in immunoblots as per the
instructions with the software.
Supporting Information
Figure S1 siRNA silencing of PhLP3 with a murine
siRNA results in the knockdown of PhLP3 mRNA levels
in CHO LB01 cells 72 h post-transfection. CHO LB01 cells
were transfected with an siRNA to PhPL3 as described in the
methods section and the levels of mRNA determined by qRT-
PCR 72 h post-transfection using a Chromo4 Real-Time PCR
Detection System (Bio-Rad Laboratories, Inc.). Total RNA was
extracted 72 h post-transfection using the RNeasy extraction kit
(Qiagen) according to the manufacturer’s instructions. For qRT-
PCR the following primers were used; Forward: 59 agtggaaatt-
taatggagcca; Reverse: 59 gtatttctttccttggatagtt and the following
PCR conditions; 50uC for 10 min followed by 95uC for 5 min,
then 95uC for 10 s and 58uC for 30 s, these last two steps being
repeated 35 times. qRT-PCR was undertaken using a QuantiFast
SYBR Green RT-PCR kit (Qiagen). Crossing point, quantifica-
tion, and melting curve analysis was undertaken using the Opticon
Monitor software (Bio-Rad Laboratories, Inc.) by normalization to
four house keeping genes. Control=no knockdown, PhPL3
KD=samples transfected with PhPL3 murine siRNA. Error bars
represent Standard Deviation from the mean (SD), n=3 biological
triplicates.
(TIF)
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